Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Symbol: 300357.SZ

SHZ

25.97

CNY

Market price today

  • 44.2441

    P/E Ratio

  • -6.3048

    PEG Ratio

  • 13.60B

    MRK Cap

  • 0.01%

    DIV Yield

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357-SZ) Financial Statements

On the chart you can see the default numbers in dynamics for Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ). Companys revenue shows the average of NaN M which is NaN % gowth. The average gross profit for the whole period is NaN M which is NaN %. The average gross profit ratio is NaN %. The net income growth for the company last year performance is NaN % which equals NaN % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to . A look back at the past year reveals a total asset change of NaN. Shareholder value, as depicted by the total shareholder equity, is valued at NaN in the reporting currency. The year over year change in this aspect is NaN%.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009

balance-sheet.row.cash-and-short-term-investments

01288.81135.71020.9
890.7
792.1
460
185.8
235.5
271.8
275.5
103.3
64.1
42
27.4
43.5

balance-sheet.row.short-term-investments

0117.4295.1370.9
307
41.4
13
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

0214.9284.9256.2
220.5
211
179.2
149.5
117.9
103.3
99.5
85.3
66.6
49.3
27.6
19.2

balance-sheet.row.inventory

05948.453.8
48.3
36.8
23.5
19.8
14
9.2
11.9
8
5
4.6
3.6
3.8

balance-sheet.row.other-current-assets

07.28.110.7
11.4
10
119
301.4
171.8
100
60
-1.5
-0.9
-1
-0.6
9

balance-sheet.row.total-current-assets

01569.91477.11341.5
1170.9
1050
781.7
656.5
539.2
484.3
446.9
195.1
134.8
95
57.9
75.5

balance-sheet.row.property-plant-equipment-net

0704.8444.6301.6
240.2
197.6
137.7
123.6
118.5
97
60.3
48.4
38.7
36.6
38.6
32.3

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0188.4189.5176.4
170.4
160.9
123.4
53.1
36.8
27.8
21.8
19.4
16.2
14.6
13.2
12.5

balance-sheet.row.goodwill-and-intangible-assets

0188.4189.5176.4
170.4
160.9
123.4
53.1
36.8
27.8
21.8
19.4
16.2
14.6
13.2
12.5

balance-sheet.row.long-term-investments

0-43.2-216.7-287.6
-293.2
-28.2
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

054.95.8
4.9
3.7
1.9
1.7
1.7
1.3
1.3
1
0.7
0.7
0.7
0.7

balance-sheet.row.other-non-current-assets

0137.2298.4394.3
311.5
44.2
13.3
13.4
0.7
1.2
1
0
0.6
0.3
0
0.4

balance-sheet.row.total-non-current-assets

0992.3720.7590.5
433.8
378.2
276.2
191.8
157.7
127.2
84.4
68.9
56.3
52.2
52.6
45.9

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

02562.22197.91932
1604.8
1428.2
1057.9
848.3
696.9
611.5
531.3
264
191.1
147.2
110.5
121.4

balance-sheet.row.account-payables

087.75.1
5.7
8.7
3.4
1.4
1
0.6
1
0.6
0.6
0.6
0.7
4.6

balance-sheet.row.short-term-debt

041.245.9
5.1
-0.2
0
0
0
0
0
0
0
10
10
0

balance-sheet.row.tax-payables

014.530.362.9
13
13.2
25.1
16.7
3.9
4.8
7.9
4.7
4.8
4
2.5
0.3

balance-sheet.row.long-term-debt-total

021.312.31.9
4.7
0
0
0
0
0
0
0
0
0
0
0

Deferred Revenue Non Current

030.927.424.9
20.6
16.1
4.9
4.9
4.9
3.9
1.6
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

0127.591.196.6
44.2
51.3
54.2
40.8
35.4
24
15.2
11.4
7.3
0
0
0.5

balance-sheet.row.total-non-current-liabilities

081.46827.4
21.2
16.2
4.9
4.9
4.9
3.9
1.6
0.9
1.8
2.7
3.5
4.4

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
-0.9
0
0
0
0

balance-sheet.row.capital-lease-obligations

021.312.31.9
4.7
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

0258.5170.8135.4
76.6
76.3
62.5
47.1
41.3
28.6
17.8
12
9.7
19.6
20.1
9.5

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

0523.6523.6523.6
523.6
523.6
290.9
161.6
161.6
161.6
161.6
90
90
90
87
126.8

balance-sheet.row.retained-earnings

01262.61092.7889.6
647.5
494.3
532.6
388.3
261.4
201.7
144.1
145.4
81.9
33.5
3.1
-15

balance-sheet.row.accumulated-other-comprehensive-income-loss

0270.7235.1194.7
156.6
124.9
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

0128.2128.2128.2
128.2
128.2
146.1
251.4
232.6
219.6
207.8
16.5
9.4
4
0.4
0

balance-sheet.row.total-stockholders-equity

02185.11979.61736.1
1455.9
1271
969.5
801.3
655.6
582.9
513.6
251.9
181.4
127.6
90.4
111.9

balance-sheet.row.total-liabilities-and-stockholders-equity

02562.22197.91932
1604.8
1428.2
1057.9
848.3
696.9
611.5
531.3
264
191.1
147.2
110.5
121.4

balance-sheet.row.minority-interest

0118.647.560.5
72.2
81
25.9
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

02303.72027.11796.6
1528.1
1352
995.4
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

074.278.483.3
13.9
13.1
13
13
0
0
0
0
0
0
0
0.4

balance-sheet.row.total-debt

062.416.37.8
9.8
0
0
0
0
0
0
0
0
10
10
0

balance-sheet.row.net-debt

0-1108.9-824.4-642.2
-573.9
-750.8
-460
-185.8
-235.5
-271.8
-275.5
-103.3
-64.1
-32
-17.4
-43.5

Cash Flow Statement

The financial landscape of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of NaN. The company recently extended its share capital by issuing NaN, marking a difference of NaN compared to the previous year. The company's investing activities resulted in net cash usage, amounting to NaN in the reporting currency. This is a shift of NaN from the previous year. In the same period, the company recorded NaN, NaN, and NaN, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of NaN, with a year over year difference of NaN. Furthermore, the company allocated NaN for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as NaN, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009

cash-flows.row.net-income

0295.5335.7326.3
269.7
292.6
231.9
186.1
129.2
117.8
99.5
70.6
53.8
37.3
18.4
10.5

cash-flows.row.depreciation-and-amortization

038.526.125.1
15
10.4
7.3
6.2
5.7
4.2
3.9
3.6
3.3
3.2
2.6
2.2

cash-flows.row.deferred-income-tax

000.5-1
-0.8
-1.7
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

00-0.51
0.8
1.7
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

047.4-47.211.5
-26.4
-69.5
-26.2
-28.1
-15.5
-7.4
-19.8
-16.9
-17.2
-22.7
-6.4
1.7

cash-flows.row.account-receivables

00-30.9-34.6
-12.2
-53
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

0-9.44.1-5.4
-11.5
-13.3
-3.6
-5.8
-4.9
2.8
-3.9
-2.9
-0.4
-1
0.2
-0.5

cash-flows.row.account-payables

00-20.952.5
-1.9
-1.5
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

056.80.5-1
-0.8
-1.7
-22.5
-22.3
-10.7
-10.2
-15.9
-14
-16.8
-21.7
-6.5
2.3

cash-flows.row.other-non-cash-items

00.745.7-2.3
-2.2
-0.5
-6.5
-5.1
3.4
0.3
0.1
1.1
1.3
1.4
-0.1
-1.8

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-209.2-188.7-122.2
-70.2
-99.8
-57.8
-34.7
-35.9
-31.5
-22.7
-17.5
-7.2
-4
-10.6
-21.5

cash-flows.row.acquisitions-net

000.20
0
0
0
0
0
0
0
0
0
0
0
21.5

cash-flows.row.purchases-of-investments

0-600.1-484.4-843.1
-363
-847
-561
-999
-496
-140
-180
0
0
0
0
-0.5

cash-flows.row.sales-maturities-of-investments

0612.2517.6742.7
337.4
328.1
753.3
865.2
428.4
101.5
121.2
0
0
0
9.8
47.3

cash-flows.row.other-investing-activites

05.137.110.2
5
11.8
-2.1
0.1
0.9
-0.1
2.6
2
0
0
0
-21.5

cash-flows.row.net-cash-used-for-investing-activites

0-191.9-118.2-212.3
-90.7
-606.9
132.4
-168.4
-102.6
-70
-78.8
-15.5
-7.2
-4
-0.7
25.4

cash-flows.row.debt-repayment

0-20-5.8-5.8
0
0
0
0
0
0
0
0
-10
-10
0
0

cash-flows.row.common-stock-issued

0000
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0-105.6-105.2-83.8
-94.2
-72.7
-64.6
-40.4
-56.6
-48.5
-30.3
0
-0.3
-0.5
0
0

cash-flows.row.other-financing-activites

077.200
0
136.5
0
0
0
0
197.5
-3.5
-1.5
10
-29.9
-27.4

cash-flows.row.net-cash-used-provided-by-financing-activities

0-23.4-111-89.6
-94.2
63.8
-64.6
-40.4
-56.6
-48.5
167.2
-3.5
-11.9
-0.5
-29.9
-27.4

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

0166.8131.158.7
71.2
-310.2
274.2
-49.7
-36.3
-3.7
172.1
39.3
22.1
14.6
-16.1
10.6

cash-flows.row.cash-at-end-of-period

0577.6410.8279.7
221
149.8
460
185.8
235.5
271.8
275.5
103.3
64.1
42
27.4
43.5

cash-flows.row.cash-at-beginning-of-period

0410.8279.7221
149.8
460
185.8
235.5
271.8
275.5
103.3
64.1
42
27.4
43.5
32.9

cash-flows.row.operating-cash-flow

0382.1360.3360.6
256.2
232.9
206.5
159.1
122.8
114.8
83.7
58.3
41.2
19.1
14.5
12.6

cash-flows.row.capital-expenditure

0-209.2-188.7-122.2
-70.2
-99.8
-57.8
-34.7
-35.9
-31.5
-22.7
-17.5
-7.2
-4
-10.6
-21.5

cash-flows.row.free-cash-flow

0172.9171.5238.4
186.1
133.1
148.7
124.4
86.8
83.3
61
40.8
33.9
15.2
4
-8.9

Income Statement Row

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s revenue saw a change of NaN% compared with the previous period. The gross profit of 300357.SZ is reported to be NaN. The company's operating expenses are NaN, showing a change of NaN% from the last year. The expenses for depreciation and amortization are NaN, which is a NaN% change from the last accounting period. Operating expenses are reported to be NaN, which shows a NaN% year-over-year change. Selling and marketing expenses are NaN, which is a NaN% change compared to the previous year. The EBITDA based on the recent numbers is NaN, representing a NaN% year-over-year growth. The operating income is NaN, which shows a NaN% change when compared to the previous year. The change in the net income is NaN%. The net income for the last year was NaN.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009

income-statement-row.row.total-revenue

0848.2896807.7
636.2
639.4
500.7
385.6
312.1
267.1
239.5
193.6
147.5
103.2
59.3
37.4

income-statement-row.row.cost-of-revenue

040.241.334.4
28.5
22.9
28.5
14.1
11.6
13.1
9.7
7.4
7.6
6.5
5.7
4.5

income-statement-row.row.gross-profit

0808854.7773.3
607.7
616.5
472.2
371.5
300.5
254
229.8
186.2
140
96.7
53.6
32.9

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0116.128.5
16.9
25.2
1.6
2.7
0.4
4.5
6.5
1.5
3
2.8
2.1
0

income-statement-row.row.operating-expenses

0494.2439.5407.2
313
298.2
218.6
164.5
150.5
125.3
122
104.4
78.8
54.3
35.7
25.9

income-statement-row.row.cost-and-expenses

0534.4480.8441.6
341.5
321
247.2
178.5
162.1
138.4
131.7
111.8
86.3
60.8
41.4
30.5

income-statement-row.row.interest-income

03124.822.6
23.3
24.2
11.3
3.9
4.5
5.3
4.5
0.9
0.5
0.3
0.7
0

income-statement-row.row.interest-expense

01.30.40.4
0.1
0.1
11.2
3.8
4.4
0
0
0
0.3
0.5
0
-1

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

012.50.1
1.1
2.3
19.4
11.9
1.8
9.9
11.1
1.3
2.2
1.6
2.8
2.9

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0116.128.5
16.9
25.2
1.6
2.7
0.4
4.5
6.5
1.5
3
2.8
2.1
0

income-statement-row.row.total-operating-expenses

012.50.1
1.1
2.3
19.4
11.9
1.8
9.9
11.1
1.3
2.2
1.6
2.8
2.9

income-statement-row.row.interest-expense

01.30.40.4
0.1
0.1
11.2
3.8
4.4
0
0
0
0.3
0.5
0
-1

income-statement-row.row.depreciation-and-amortization

038.575.927.2
-14.1
-13.7
7.3
6.2
5.7
4.2
3.9
3.6
3.3
3.2
2.6
2.2

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

0345396.2392.9
321.5
343.4
271.4
216.2
156
134.1
112.4
81.7
60.4
41.2
18.6
9.8

income-statement-row.row.income-before-tax

0346398.7393
322.6
345.7
273
219
151.8
138.6
118.9
83.1
63.4
43.9
20.7
9.8

income-statement-row.row.income-tax-expense

050.46366.7
52.9
53.1
41.1
32.9
22.6
20.8
19.3
12.6
9.6
6.7
2.3
-0.7

income-statement-row.row.net-income

0310.2348.8338
278.4
298.3
232.9
186.1
129.2
117.8
99.6
70.6
53.8
37.3
18.4
10.5

Frequently Asked Question

What is Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) total assets?

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) total assets is 2562166715.000.

What is enterprise annual revenue?

The annual revenue is N/A.

What is firm profit margin?

Firm profit margin is 0.953.

What is company free cash flow?

The free cash flow is 0.312.

What is enterprise net profit margin?

The net profit margin is 0.360.

What is firm total revenue?

The total revenue is 0.392.

What is Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) net profit (net income)?

The net profit (net income) is 310184878.000.

What is firm total debt?

The total debt is 62443059.000.

What is operating expences number?

The operating expences are 494184515.000.

What is company cash figure?

Enretprise cash is 0.000.